Neurological Disorder Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL NEUROLOGICAL DISORDER DRUGS INDUSTRY

2.1 Summary about Neurological Disorder Drugs Industry

2.2 Neurological Disorder Drugs Market Trends

2.2.1 Neurological Disorder Drugs Production & Consumption Trends

2.2.2 Neurological Disorder Drugs Demand Structure Trends

2.3 Neurological Disorder Drugs Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Antipsychotic

4.2.2 Hypnotic & Sedative

4.2.3 Analgesics

4.2.4 Anticoagulants

4.2.5 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital

4.3.2 Clinic

4.3.3 Home

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Antipsychotic

5.2.2 Hypnotic & Sedative

5.2.3 Analgesics

5.2.4 Anticoagulants

5.2.5 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital

5.3.2 Clinic

5.3.3 Home

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Antipsychotic

6.2.2 Hypnotic & Sedative

6.2.3 Analgesics

6.2.4 Anticoagulants

6.2.5 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital

6.3.2 Clinic

6.3.3 Home

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Antipsychotic

7.2.2 Hypnotic & Sedative

7.2.3 Analgesics

7.2.4 Anticoagulants

7.2.5 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital

7.3.2 Clinic

7.3.3 Home

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Antipsychotic

8.2.2 Hypnotic & Sedative

8.2.3 Analgesics

8.2.4 Anticoagulants

8.2.5 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital

8.3.2 Clinic

8.3.3 Home

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Antipsychotic

9.2.2 Hypnotic & Sedative

9.2.3 Analgesics

9.2.4 Anticoagulants

9.2.5 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital

9.3.2 Clinic

9.3.3 Home

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Novartis AG

10.1.2 GlaxoSmithKline plc

10.1.3 Merck & Co.

10.1.4 Bayer AG

10.1.5 AstraZeneca

10.1.6 Boehringer Ingelheim GmbH

10.1.7 Teva Pharmaceutical Industries Ltd

10.2 Neurological Disorder Drugs Sales Date of Major Players (2017-2020e)

10.2.1 Novartis AG

10.2.2 GlaxoSmithKline plc

10.2.3 Merck & Co.

10.2.4 Bayer AG

10.2.5 AstraZeneca

10.2.6 Boehringer Ingelheim GmbH

10.2.7 Teva Pharmaceutical Industries Ltd

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Neurological Disorder Drugs Product Type Overview

2.Table Neurological Disorder Drugs Product Type Market Share List

3.Table Neurological Disorder Drugs Product Type of Major Players

4.Table Brief Introduction of Novartis AG

5.Table Brief Introduction of GlaxoSmithKline plc

6.Table Brief Introduction of Merck & Co.

7.Table Brief Introduction of Bayer AG

8.Table Brief Introduction of AstraZeneca

9.Table Brief Introduction of Boehringer Ingelheim GmbH

10.Table Brief Introduction of Teva Pharmaceutical Industries Ltd

11.Table Products & Services of Novartis AG

12.Table Products & Services of GlaxoSmithKline plc

13.Table Products & Services of Merck & Co.

14.Table Products & Services of Bayer AG

15.Table Products & Services of AstraZeneca

16.Table Products & Services of Boehringer Ingelheim GmbH

17.Table Products & Services of Teva Pharmaceutical Industries Ltd

18.Table Market Distribution of Major Players

19.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

20.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

21.Table Global Neurological Disorder Drugs Market Forecast (Million USD) by Region 2021f-2026f

22.Table Global Neurological Disorder Drugs Market Forecast (Million USD) Share by Region 2021f-2026f

23.Table Global Neurological Disorder Drugs Market Forecast (Million USD) by Demand 2021f-2026f

24.Table Global Neurological Disorder Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f